Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Total Liabilities (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Total Liabilities for 6 consecutive years, with -$341.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities fell 429.35% year-over-year to -$341.7 million, compared with a TTM value of -$341.7 million through Dec 2025, down 429.35%, and an annual FY2025 reading of -$341.7 million, down 429.35% over the prior year.
  • Total Liabilities was -$341.7 million for Q4 2025 at Cytek Biosciences, down from $116.3 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $116.3 million in Q3 2025 and bottomed at -$379.6 million in Q1 2025.
  • Average Total Liabilities over 5 years is $40.7 million, with a median of $94.3 million recorded in 2022.
  • The sharpest move saw Total Liabilities soared 7943.7% in 2022, then crashed 481.71% in 2025.
  • Year by year, Total Liabilities stood at $57.9 million in 2021, then soared by 62.17% to $93.9 million in 2022, then increased by 7.95% to $101.4 million in 2023, then grew by 2.34% to $103.8 million in 2024, then plummeted by 429.35% to -$341.7 million in 2025.
  • Business Quant data shows Total Liabilities for CTKB at -$341.7 million in Q4 2025, $116.3 million in Q3 2025, and $115.8 million in Q2 2025.